GoPlus: Multiple early-stage x402 projects found with high-risk issues such as excessive permissions, unlimited minting, HonyPot, and signature replay attacks
Foresight News reported that GoPlus released the x402 ecosystem risk scan report, stating that several early x402 projects have high-risk issues such as excessive permissions, unlimited minting, HoneyPot, and signature replay. Among them, @402bridge experienced a permissions vulnerability that led to the theft of USDC from over 200 users, and Hello402 also saw a price drop due to unlimited minting and liquidity issues. AI scanning shows that the following projects all have serious risks of directly draining assets or bypassing authorization. Users are reminded to be cautious of early x402 MEME project risks:
- FLOCK (0x5ab3): The transferERC20 function allows the owner to withdraw any amount of any token from the contract.
- x420 (0x68e2): The crosschainMint function can mint tokens without limitation.
- U402 (0xd2b3): The mintByBond function allows the bond to mint tokens without limitation.
- MRDN (0xe57e): The drawbackToken function allows the owner to withdraw any amount of any token from the contract.
- PENG (0x4444ee, 0x444450, 0x444428): The manualSwap function allows the owner to withdraw ETH from the contract, while the transferFrom function bypasses permission checks for special accounts.
- x402Token (0x40ff): The transferFrom function bypasses permission checks for special accounts.
- x402b (0xd8af5f): The manualSwap function allows the owner to withdraw ETH from the contract, while the transferFrom function bypasses permission checks for special accounts.
- x402MO (0x3c47df): The manualSwap function allows the owner to withdraw ETH from the contract, while the transferFrom function bypasses permission checks for special accounts.
- H402 (old version) (0x8bc76a): The drawbackDevToken function allows the owner to mint tokens directly, while the addTokenCredits + redeemTokenCredits functions can achieve unlimited minting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
S-Energy Clarifies Solar Contract Value at KRW 11.04 Billion, Reflecting Its Share
Why Snap Needed an Iron Man Star Before Its $2,195 Glasses Go on Sale

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475
Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million
Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.
